Stem cell treatments could come by 2005

韩雪娜

日期: 2002-10-25 今日/总浏览: 1/1562+ V8 X3 l- e/ W' R

7 R$ w. ]; M2 }- s- ]( q; a  V9 P6 Y) i* p, F4 v9 X, j. L
' B; H$ g! U1 D* a0 W4 G

- |2 u. s$ o0 P7 A2 qThefirstcommerciallyavailablestemcell-derivedproductslikelywillcomefromadultstemcellsandbeforthetreatmentofneurologicaldisorderssuchasParkinson'sandAlzheimer'sdisease,theheadofanadultstemcellcompanytoldUnitedPressInternational.6 A2 P6 I0 k; o/ |# p
Theproductscouldbeavailableinthenextthreeyears,saidMartinMcGlynn,presidentandchiefexecutiveofficerofStemCellsInc.,ofPaloAlto,Calif.,whichisworkingtodevelopmedicaltreatmentsderivedfromadultstemcells.McGlynnwasexpectedtomakesimilarremarksatTechvest's4thAnnualHealthcareConference&ExpoinBostonWednesday.
& f4 w1 q/ g: I- m4 K) ]- EStemcellshavetheabilitytogiverisetodifferentcelltypesinthebody.Theyhavethepotentialtoreplacetissuesdamagedbydisease.7 `5 W1 J+ n9 \/ ~4 z# m
Embryonicstemcellscangiverisetoanycelltypeandthushavethegreatestpotentialtotreatthewidestrangeofdiseases.However,theyarecontroversialbecauseharvestingthemrequiresthedestructionofembryos.Adultstemcells,whichcanbederivedfromadulttissueswithoutharmingthedonor,offeralesscontroversialalternative,althoughtheycangiveriseonlytoalimitednumberofcelltypes.
; A9 I7 q4 T2 f% m: W2 F- VMypredictionisthat...we'relikelytoseeoneortwostemcellproductsonthemarketinthisdecade,McGlynnsaid.Productsderivedfromadultstemcellsarelikelytobethefirstproductsbecausethesearefurtheralonginthedevelopmentprocessanddon'thavealltheregulatoryhurdlesthatareassociatedwithembryonicstemcells,hesaid.
! S" J( L$ p; C8 \) LSuchproductsprobablywillappearonthemarketstartingfromaround2005andcontinuinginthebackhalfofthisdecade,hesaid.
! Z! ?' l+ k4 F$ [McGlynnpredictedthefirstproductswouldbetreatmentsfordegenerativediseasesofthecentralnervoussystem,includingParkinson's,Alzheimer's,strokeandparalysis.8 Z0 j( n2 C$ ?( s6 a
Iwouldagreewith(McGlynn)thatsomeoftheearliestproductstoreachcommercializationwillbeforneurologicaldisorders,LindaPowers,managingdirectorofToucanCapital,aventurecapitalfirminBethesda,Md.,toldUPI.It'sstillupintheairwhether(thefirstproducts)willbeadultorembryonicstemcells,addedPowers,whosefirmhasmadeinvestmentsinbothadultandembryonicstemcellcompanies.
. m' O; a9 ^3 J# @, UWereallyarelookingacrosstheboardatadultandembryonicstemcells,Powerssaid.We'renottiltingonewayortheother.Wewanttoseewhatlookslikeitproducesthebestresultsandgofromthere.It'stooearlytotellwhichlineofcellswillbethefirsttoreachthemarket,sheadded.! R3 {% D0 }" }% `2 J+ m, x
McGlynnsaidheexpectsembryonicstemcellseventuallytobecommercializedaswell.Subjecttotheavailabilityofcapital,Iwouldanticipateembryonicstemcellsciencewillcontinuetobeworkedonandimproved,hesaid.Overtime,scientistsmightlearnhowtofullyunlockthepotentialofembryonicstemcellsanddevelopthemasdiseasetreatments,hesaid.. D$ I$ w0 ~4 i/ R7 [
Dependingoneconomicsandthedisease-treatingcapabilityofeachcellline,McGlynnadded,Wecouldhaveboth(adultandembryonicstemcell-derivedproducts)outthereonthemarket.7 N4 x- o! H, X
3 P. C; W/ }6 h: l
* C/ a+ U/ v7 M4 R
! x* w7 j' |$ ?5 Y. y
7 i: R3 c: p; L* @0 E4 M

% s" P- g% C4 e8 d& s+ h作者: Steve Mitchell
* P  G# Z6 z; r; H1 X* ]# |4 w  u3 x来源: UPI Medical Correspondent
- a# ?- w! n- x2 W3 w发布者: 刘斌